Investigational drug · Phase 2
NWRD09
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for High-grade Squamous Intraepithelial Lesion (HSIL), Persistent HPV16 Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "NWRD09"
First trial start
2026
Aug 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NWRD09", any sponsor or status.
Conditions studied
As listed on its trial records.
- High-grade Squamous Intraepithelial Lesion (HSIL)
- Persistent HPV16 Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "NWRD09" as an intervention, largest first.
- Evaluation of NWRD09 for HPV-16 Related Cervical HSILPivotal-lookingNot yet recruiting
Newish Biotech (Wuxi) Co., Ltd.Industry
NCT07712692 · 156 participants (planned) · Start Aug 1, 2026 · Primary completion Jun 30, 2027
Drug: NWRD09 Injection; NWRD09 Placebo · For: High-grade Squamous Intraepithelial Lesion (HSIL)
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 15 sites in all
Newish Biotech (Wuxi) Co., Ltd.Industry
NCT07536282 · 78 participants (planned) · Start Oct 2026 · Primary completion Sep 2027
Drug: NWRD09; Placebo · For: Persistent HPV16 Infection
Sites: New York, New York
Newish Biotech (Wuxi) Co., Ltd.Industry
NCT07710703 · 60 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 30, 2026
Drug: NWRD09/ Placebo administered by IM injection · For: Persistent Cervical HPV16 Infection
Sites: Beijing, China
- NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.Status unknown
Newish Technology (Beijing) Co., Ltd.Industry
NCT06741150 · 18 participants (planned) · Start Jun 24, 2024 · Primary completion Dec 31, 2025
Drug: NWRD09 administered by intramuscular injection · For: Intraepithelial Neoplasia; Cervical Cancer
Sites: Wuxi, China
Newish Technology (Beijing) Co., Ltd.Industry
NCT07092007 · 18 participants (planned) · Start Jun 5, 2024 · Primary completion Dec 31, 2025
Drug: NWRD09 administered by intramuscular injection · For: Intraepithelial Neoplasia; Cervical Cancer
Sites: Heze, China
Newish Biotech (Wuxi) Co., Ltd.Industry
NCT07710664 · 10 participants (planned) · Start Jul 20, 2026 · Primary completion Dec 30, 2026
Drug: NWRD09 · For: Persistent HPV16 Infection
Sites: Beijing, China
- NWRD09 for HPV-16 Related Cervical HSILRecruiting
Newish Biotech (Wuxi) Co., Ltd.Industry
NCT07047989 · 9 participants (planned) · Start Jun 12, 2025 · Primary completion Jul 31, 2026
Drug: NWRD09 injection · For: High-grade Squamous Intraepithelial Lesion (HSIL)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.